Accueil / Tag Archives: Washington (page 3)

Tag Archives: Washington

Omeros Corporation to Announce Fourth Quarter and Year-End 2018 Financial Results on March 1, 2019

Tuesday, February 26th 2019 at 12:00pm UTC SEATTLE–(BUSINESS WIRE)– Omeros Corporation (NASDAQ: OMER), today announced that the company will issue its fourth quarter and year-end 2018 financial results for the period ended December 31, 2018, on Friday, March 1, 2019, before the market opens. Omeros management will host a conference …

Plus »

Merck to Acquire Immune Design

Thursday, February 21st 2019 at 11:45am UTC Acquisition Bolsters Capabilities in Vaccine Development for Infectious Diseases and Cancer KENILWORTH, N.J. & SEATTLE & SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)– Merck (NYSE:MRK), known as MSD outside the United States and Canada, and Immune Design (NASDAQ:IMDZ), today announced that the companies have entered …

Plus »

Omeros Corporation Announces USAN and INN Selection of Nonproprietary Name for OMS721

Wednesday, February 20th 2019 at 1:30pm UTC SEATTLE–(BUSINESS WIRE)– Omeros Corporation (Nasdaq: OMER) today announced that, as the company prepares for planned commercialization of OMS721, the United States Adopted Names (USAN) Council, in consultation with the World Health Organization’s International Nonproprietary Names (INN) Expert Committee, has selected for the drug …

Plus »

Alpine Immune Sciences Presents Preclinical ALPN-101 GvHD Data at the 2019 Transplantation & Cellular Therapy Meetings of ASBMT and CIBMTR (TCT Meetings)

Tuesday, February 19th 2019 at 12:00pm UTC Appoints Immunology Veteran Vijay Kuchroo, DVM, PhD to Scientific Advisory Board SEATTLE–(BUSINESS WIRE)– Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer, autoimmune/inflammatory, and other diseases, today announced it will present preclinical GvHD data from …

Plus »

Omeros Corporation Streamlines Path to Biologics License Application for OMS721 in HSCT-TMA Following Meeting with FDA

Thursday, February 14th 2019 at 1:30pm UTC Patient Data from Existing Single-Arm Study Will Form the Basis for BLA; No Historical Control Required SEATTLE–(BUSINESS WIRE)– Omeros Corporation (Nasdaq: OMER) today announced that, based on a recent meeting with the U.S. Food and Drug Administration (FDA), the company has streamlined the …

Plus »

Omeros Corporation Appoints Thomas F. Bumol, Ph.D., to Board of Directors

Tuesday, February 12th 2019 at 1:30pm UTC — Former Lilly Biotechnology and Immunology Senior Vice President Drawn by Omeros’ Complement Franchise and Novel-Product Pipeline — SEATTLE–(BUSINESS WIRE)– Omeros Corporation (NASDAQ: OMER) today announced the appointment of Thomas F. Bumol, Ph.D., to its Board of Directors. Dr. Bumol is Executive Director …

Plus »

Seattle Genetics Achieves $30 Million Milestone Payment for European Commission Approval of ADCETRIS® (Brentuximab Vedotin) in Frontline Hodgkin Lymphoma

Monday, February 11th 2019 at 1:00pm UTC BOTHELL, Wash.–(BUSINESS WIRE)– Seattle Genetics, Inc. (Nasdaq:SGEN) today announced that its collaborator, Takeda Pharmaceutical Company Limited, received approval from the European Commission to extend the marketing authorization for ADCETRIS (brentuximab vedotin) to include ADCETRIS in combination with AVD (Adriamycin®, vinblastine and dacarbazine) in …

Plus »

Alpine Immune Sciences Announces First Subjects Dosed in Phase I Clinical Trial for Lead Autoimmune/Inflammatory Disease Program ALPN-101

Monday, February 11th 2019 at 12:00pm UTC First Dual ICOS/CD28 Inhibitor to Enter Clinical Trials SEATTLE–(BUSINESS WIRE)– Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer, autoimmune/inflammatory, and other diseases, today announced successful initiation of dosing in its first-in-human Phase I study …

Plus »

Seattle Genetics Reports Fourth Quarter and Full Year 2018 Financial Results

Thursday, February 7th 2019 at 9:02pm UTC -ADCETRIS® (Brentuximab Vedotin) Net Sales in U.S. and Canada of $476.9 Million in 2018, Including $132.1 Million in the Fourth Quarter- -ADCETRIS Approved by FDA in Combination with Chemotherapy for Frontline CD30-Expressing PTCL- -Top-line Data from Enfortumab Vedotin Pivotal Trial in Metastatic Urothelial …

Plus »

Seattle Genetics to Present at Guggenheim Healthcare Talks Idea Forum | Oncology Day

Wednesday, February 6th 2019 at 1:00pm UTC BOTHELL, Wash.–(BUSINESS WIRE)– Seattle Genetics, Inc. (Nasdaq:SGEN) announced today that management will present at the Guggenheim Healthcare Talks Idea Forum | Oncology Day on Thursday, February 14, 2019 at 2:00 p.m. Eastern Time. The presentation will be webcast live and available for replay …

Plus »
>
Macbook Pro
* Intel Core i7 (3.8GHz, 6MB cache)
* Retina Display (2880 x 1880 px)
* NVIDIA GeForce GT 750M (Iris)
* 802.11ac Wi-Fi and Bluetooth 4.0
* Thunderbolt 2 (up to 20Gb/s)
* Faster All-Flash Storage (X1)
* Long Lasting Battery (9 hours)
BIENVENUE CHEZ BIOTECH FINANCES
Vous appréciez nos informations ?
Recevez nos alertes, nos dernières actualités, suivez-nous, enregistrez-vous gratuitement, rejoignez notre communauté. Merci à vous !
ARE YOU READY? GET IT NOW!
Increase more than 500% of Email Subscribers!
Your Information will never be shared with any third party.
DÉCOUVREZ LA SOLUTION STRATA !
PGlmcmFtZSB3aWR0aD0iMTAwJSIgaGVpZ2h0PSIxMDAlIiBzcmM9Imh0dHBzOi8vd3d3LmJpb3RlY2gtZmluYW5jZXMuY29tL3dwLWNvbnRlbnQvdXBsb2Fkcy8yMDE1LzA3L1NhdHJhLTIubXA0IiBmcmFtZWJvcmRlcj0iMCIgYWxsb3dmdWxsc2NyZWVuPjwvaWZyYW1lPg==
Retrouvez nous sur http://stratahealth.com/fr/
Un ensemble de solutions performantes
pour assurer le continuum de vos données.
Biotech Finances
SUIVEZ-NOUS, ENREGISTREZ-VOUS !
PGlmcmFtZSB3aWR0aD0iMTAwJSIgaGVpZ2h0PSIxMDAlIiBzcmM9Imh0dHA6Ly93d3cueW91dHViZS5jb20vZW1iZWQvajhsU2NITzJtTTAiIGZyYW1lYm9yZGVyPSIwIiBhbGxvd2Z1bGxzY3JlZW4+PC9pZnJhbWU+
All rights reserved © Company Name, 2014
Concours Genopole Young Biotech Award
* 100 000 € pour la meilleure Biotech
* Réservé aux biotechs hors santé
* 6 mois d'hébergement gratuit
* Un accompagnement personnalisé
* Etude de marché offerte
* Expertise du projet par EY
* Et nombre d'autres avantages...
S'inscrire au 15H BIOTECH EXPRESS
Chaque jour à 15H recevez gratuitement les news des biotechs, des medtechs,et des fonds spécialisés. Levées ; partenariats ; nominations ; fusacq ; closing ; milestone...
2019 (C) All rights reserved.

En cochant cette case, j’accepte la Politique de confidentialité de ce site et de recevoir des informations de notre part.

S'inscrire au 15H BIOTECH EXPRESS
Chaque jour à 15H recevez gratuitement les news des biotechs, des medtechs,et des fonds spécialisés. Levées ; partenariats ; nominations ; fusacq ; closing ; milestone...
2019 (C) All rights reserved.

En cochant cette case, j’accepte la Politique de confidentialité de ce site et de recevoir des informations de notre part.